Determination of compound-specific acceptable daily intakes for 11 mutagenic carcinogens used in pharmaceutical...

Area of Science:

• Pharmaceutical Chemistry
• Toxicology
• Regulatory Science

Background:

• Pharmaceutical synthesis can result in impurities, including those with mutagenic and carcinogenic potential.
• Regulatory guidelines exist to minimize exposure, but compound-specific recommendations for impurities are limited.
• Controlling potentially harmful impurities is crucial for drug safety and regulatory compliance.

Purpose of the Study:

• To present practical experience in deriving acceptable daily intakes (ADIs) for 11 specific pharmaceutical impurities.
• To summarize genotoxicity and carcinogenicity data for these impurities.
• To highlight challenges in calculating ADIs based on carcinogenicity data for mutagenic carcinogens.

Main Methods:

• Compilation and summary of genotoxicity and carcinogenicity data for 11 pharmaceutical impurities.
• Description of the methodology used to derive acceptable daily intakes (ADIs) for each impurity.
• Analysis of considerations and challenges in calculating ADIs from carcinogenicity data.

Main Results:

• Detailed ADI derivation for 11 pharmaceutical impurities, including those identified as mutagenic carcinogens.
• Summary of relevant genotoxicity and carcinogenicity data.
• Identification of key challenges in establishing ADIs for complex impurity profiles.

Conclusions:

• The presented approach for deriving ADIs provides a practical reference for the pharmaceutical industry.
• Effective impurity control strategies are essential, especially for mutagenic carcinogens.
• Further research and standardized methodologies may be needed for robust ADI calculations for pharmaceutical impurities.